ArticleCancer discovery2026

HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies.

Marie-Anne Goyette et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.